Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

NCT03636659 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Visceral Leishmaniasis

Interventions

DRUG: Amphotericin B Liposome
DRUG: AmBisome (Amphotericin B) Liposome

Sponsor

Aurobindo Pharma Ltd

Collaborators

[object Object]